The BIO Asia 2017 meeting is an exclusive partnering forum offering an unique possibility to find and evaluate oncology opportunities in an Asian setting (1stOncology Insights, BioSeeker Group, MAR 1, 2017, http://www.bioseeker.com/market-research-report/finding-and-evaluating-oncology-opportunities-at-bio-asia-2017-a-1stoncology-insights-report.html [SID1234518080]).
In a recent analysis, based on the communicated participants at the time*, the oncology position and activities of 61 companies has been featured by the analyst team at 1stOncology for the benefit its audience. In overall, an extensive partnering review has been done of close to 900, partnered or as yet un-partnered, drugs in 17 "hot" areas in oncology, including:
· Most recent Positive/Negative Developments (226/43)
· Start-Ups (4)
· Fierce 15 Drugs (53)
· Orphan Drugs (252)
· Breakthrough Therapies (31)
· Cancer Vaccines (59)
· CAR/TCR Therapies (14)
· Immune Checkpoints (67)
· Epigenetic Therapies (35)
· Protein Kinase Inhibitors (194)
· Antibodies in Oncology (345)
· Cancer Peptides (47)
· RNA Therapies (13)
· Conjugated Drugs (109)
· Biomarker/Companion Diagnostic Drugs (166)
· Combination Therapy Drugs (492)
· Biosimilars/Biobetters (27)
Area (Number of Drugs in Each Area)
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This independent, third-party breakdown analysis gives a landscape of oncology opportunities which guides corporate interest in how to allocate time and spend resources around BIO Asia where it reaps the most value. Undoubtedly, immuno-oncology will continue being the center piece of attention in general and immunecheck point inhibitors in particular.
Furthermore almost one thousand corporate developments have been analyzed detailing the latest positive and negative pipeline development for circa 250 top cancer drugs throughout 2016 to present, giving a comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.
The 1stOncology team recognizes that contacts are key to actively drive forward partnering activities so special for BIO Asia 2017 they have set out to boost the event with giving access to circa 300 contacts in business development and licensing people within the featured companies, allowing the thrifty to reach out quickly and directly to the right person of interest for initial introductions, partnership discussions, pre-booking meetings etc.
*As of February 24, 2017